DexCom, Inc. (DXCM) DCF Valuation

DexCom, Inc. (DXCM) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

DexCom, Inc. (DXCM) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Whether you're an investor or analyst, this DXCM DCF Calculator is your go-to resource for accurate valuation. Loaded with real data from DexCom, Inc., you can adjust forecasts and observe the effects in real-time.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 1,476.0 1,926.7 2,448.5 2,909.8 3,622.3 4,536.4 5,681.2 7,115.0 8,910.5 11,159.1
Revenue Growth, % 0 30.54 27.08 18.84 24.49 25.24 25.24 25.24 25.24 25.24
EBITDA 213.2 376.8 377.5 565.3 916.7 854.2 1,069.8 1,339.8 1,677.9 2,101.3
EBITDA, % 14.44 19.56 15.42 19.43 25.31 18.83 18.83 18.83 18.83 18.83
Depreciation 48.7 67.1 101.9 155.9 186.0 194.5 243.6 305.0 382.0 478.4
Depreciation, % 3.3 3.48 4.16 5.36 5.13 4.29 4.29 4.29 4.29 4.29
EBIT 164.5 309.7 275.6 409.4 730.7 659.7 826.2 1,034.8 1,295.9 1,622.9
EBIT, % 11.14 16.07 11.26 14.07 20.17 14.54 14.54 14.54 14.54 14.54
Total Cash 1,533.3 2,707.7 2,731.2 2,456.2 2,724.1 4,170.0 5,222.4 6,540.3 8,190.8 10,257.8
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 286.3 428.5 516.6 752.2 987.5
Account Receivables, % 19.4 22.24 21.1 25.85 27.26
Inventories 119.8 234.7 357.3 306.7 559.6 552.4 691.7 866.3 1,084.9 1,358.7
Inventories, % 8.12 12.18 14.59 10.54 15.45 12.18 12.18 12.18 12.18 12.18
Accounts Payable 102.3 163.3 189.4 237.9 276.4 353.4 442.5 554.2 694.1 869.3
Accounts Payable, % 6.93 8.48 7.74 8.18 7.63 7.79 7.79 7.79 7.79 7.79
Capital Expenditure -180.0 -199.0 -389.2 -364.8 -236.6 -521.6 -653.2 -818.0 -1,024.5 -1,283.0
Capital Expenditure, % -12.2 -10.33 -15.9 -12.54 -6.53 -11.5 -11.5 -11.5 -11.5 -11.5
Tax Rate, % 23.78 23.78 23.78 23.78 23.78 23.78 23.78 23.78 23.78 23.78
EBITAT 159.6 679.4 245.2 357.4 557.0 593.1 742.8 930.3 1,165.0 1,459.1
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -275.5 351.4 -226.7 12.0 56.7 286.7 17.7 22.2 27.8 34.8
WACC, % 9.59 9.6 9.56 9.56 9.52 9.56 9.56 9.56 9.56 9.56
PV UFCF
SUM PV UFCF 334.7
Long Term Growth Rate, % 4.00
Free cash flow (T + 1) 36
Terminal Value 651
Present Terminal Value 412
Enterprise Value 747
Net Debt 2,028
Equity Value -1,281
Diluted Shares Outstanding, MM 426
Equity Value Per Share -3.01

What You Will Get

  • Real DexCom Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on DexCom’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.

Key Features

  • Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for DexCom, Inc. (DXCM).
  • WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with customizable inputs specific to DexCom, Inc. (DXCM).
  • Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit DexCom, Inc. (DXCM) projections.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to DexCom, Inc. (DXCM).
  • Visual Dashboard and Charts: Provides visual outputs that summarize key valuation metrics for straightforward analysis of DexCom, Inc. (DXCM).

How It Works

  • Step 1: Download the prebuilt Excel template featuring DexCom’s data included.
  • Step 2: Review the pre-filled sheets to familiarize yourself with the key metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see recalculated results, including DexCom’s intrinsic value.
  • Step 5: Make informed investment decisions or create reports based on the outputs.

Why Choose This Calculator for DexCom, Inc. (DXCM)?

  • Comprehensive Tool: Features DCF, WACC, and financial ratio analyses all in one convenient package.
  • Customizable Inputs: Modify the yellow-highlighted cells to explore different scenarios.
  • Detailed Insights: Automatically computes DexCom’s intrinsic value and Net Present Value.
  • Preloaded Data: Historical and projected data provide reliable starting points for analysis.
  • Professional Quality: Perfect for financial analysts, investors, and business consultants.

Who Should Use This Product?

  • Healthcare Investors: Make informed decisions with an advanced valuation tool tailored for biotech companies.
  • Market Analysts: Streamline your analysis with a ready-to-use DCF model specifically designed for DexCom, Inc. (DXCM).
  • Consultants: Effortlessly modify the template for client reports or presentations focused on diabetes management solutions.
  • Health Tech Enthusiasts: Enhance your knowledge of valuation methods through practical, real-world applications.
  • Educators and Students: Utilize it as a hands-on resource in courses related to healthcare finance.

What the Template Contains

  • Pre-Filled DCF Model: DexCom’s financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate DexCom’s profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.